My watch list  

34 Current news about the topic ulcerative colitis


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Cells that destroy the intestine

Medical researchers discover a type of cell which induces acute inflammatory episodes in bowel diseases


More than 4000,000 people in Germany are affected by the chronic inflammatory bowel diseases Morbus Crohn or ulcerative colitis. Patients often suffer from flare-ups, which damage intestinal tissue. Until now, little has been known about what actually causes flare-ups. Working together with ...


image description
Immune cells that keep gut fungi under control


Immune cells that process food and bacterial antigens in the intestines control the intestinal population of fungi, according to a new study from Weill Cornell Medicine scientists. Defects in the fungus-fighting abilities of these cells may contribute to some cases of Crohn's disease and other ...


Potent parasite protein - New therapeutic options for inflammatory bowel conditions?


A single protein from a worm parasite may one day offer new therapeutic options for treating inflammatory bowel diseases like Crohn’s or Ulcerative Colitis, that avoid the potentially serious side effects of current immunosuppressant medications. The study demonstrates the discovery of a distinct ...


New model developed to study inflammatory bowel disease in human biopsy samples


Inflammatory bowel disease (IBD) is a complex condition that requires a lifetime of care and increases a person's cancer risk. But its origins are still a mystery. Now, a team of researchers have created a new culture model of the human intestine where living tissue from a patient biopsy can be ...


Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment


Analysis reported clinical improvements with up to 152 weeks of vedolizumab treatment seen in patients with moderately to severely active ulcerative colitis Takeda Pharmaceutical Company Limited announced that the interim findings from the GEMINI Long-Term Safety (LTS) study were presented during ...


enGene raises CAD 13.5 million to develop intestinal gene delivery platform


enGene Inc. announced the closing of a $13.5 million Series B investment round led by Forbion Capital Partners, with participation of new investors Québec’s Fonds de solidarité FTQ and Pharmstandard International S.A.. Existing investor Lumira Capital via its Merck Lumira Biosciences Fund, which ...


Yale study identifies possible bacterial drivers of IBD


Yale University researchers have identified a handful of bacterial culprits that may drive inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, using patients' own intestinal immune responses as a guide. The findings are published Aug. 28 in the journal ...


EMA recommends approval of a locally targeted treatment for ulcerative colitis

Entyvio (vedolizumab) offers a treatment option for patients who do not respond to standard therapies


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Entyvio (vedolizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis or Crohn’s disease, who have had an ...


Deadly immune ‘storm’ caused by emergent flu infections


Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus. Their findings, published in the online edition of the Proceedings of the ...


Vedolizumab is an effective treatment for Crohn's disease and ulcerative colitis


An international clinical trial led by Dr. Brian Feagan of Western University in London, Canada, has found that the investigational antibody vedolizumab is an effective treatment for those suffering from ulcerative colitis (UC) and Crohn's disease (CD) when other treatments have failed. The ...


Page 1 From 4
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE